Design Therapeutics, Inc.
General ticker "DSGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $615.7M (TTM average)
Design Therapeutics, Inc. follows the US Stock Market performance with the rate: 43.6%.
Estimated limits based on current volatility of 5.2%: low 9.50$, high 10.54$
Factors to consider:
- Total employees count: 54 (0.0%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Limited operating history, Operational and conduct risks, Clinical trial failure, Regulatory and compliance, Capital raising
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.45$, 12.96$]
- 2026-12-31 to 2027-12-31 estimated range: [3.97$, 9.94$]
Financial Metrics affecting the DSGN estimates:
- Positive: with PPE of -7.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: Shareholder equity ratio, % of 93.94 > 81.92
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: 0 < Industry inventory ratio change (median), % of 0
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term DSGN quotes
Long-term DSGN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $78.19MM | $62.38MM | $79.47MM |
| Operating Income | $-78.19MM | $-62.38MM | $-79.47MM |
| Non-Operating Income | $11.33MM | $12.79MM | $9.68MM |
| R&D Expense | $57.06MM | $44.35MM | $59.13MM |
| Income(Loss) | $-66.86MM | $-49.59MM | $-69.79MM |
| Net Income(Loss)* | $-66.86MM | $-49.59MM | $-69.79MM |
| Stockholders Equity | $277.69MM | $242.10MM | $212.50MM |
| Assets | $289.64MM | $252.09MM | $226.20MM |
| Operating Cash Flow | $-58.56MM | $-43.10MM | $-54.36MM |
| Capital expenditure | $0.26MM | $0.34MM | $0.19MM |
| Investing Cash Flow | $52.54MM | $43.95MM | $22.91MM |
| Financing Cash Flow | $0.72MM | $0.51MM | $25.74MM |
| Earnings Per Share** | $-1.19 | $-0.88 | $-1.22 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.